Stay updated on SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial
Sign up to get notified when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.

Latest updates to the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page revision was updated from v3.4.1 to v3.4.2. No user-facing content or functionality was altered.SummaryDifference0.0%

- Check19 days agoChange DetectedThe page shows a minor version bump from v3.4.0 to v3.4.1, a routine update with no visible changes to study details or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedShow glossary option added and QC-related labels updated to 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. The earlier entries 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' have been removed.SummaryDifference0.2%

- Check35 days agoChange DetectedRecruitment status updated from Recruiting to Active, not recruiting; the locations count is updated to 18 and multiple contact details and site listings were removed or updated.SummaryDifference7%

- Check42 days agoChange Detected- Revision: v3.3.4 updated from v3.3.3. No functional changes are indicated.SummaryDifference0.0%

- Check64 days agoChange DetectedAdded a consolidated Locations section listing Arizona, Florida, Kentucky, Massachusetts, Michigan, Missouri, New York, Ohio, Pennsylvania, Texas, Wisconsin, Alberta, and Quebec; removed the prior individual location subsections; version updated to v3.3.3.SummaryDifference1%

Stay in the know with updates to SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.